Ascentage Pharma Group International (AAPG) Long-Term Deferred Tax: 2022-2025

  • Ascentage Pharma Group International's Long-Term Deferred Tax was N/A to $4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.6 million, marking a year-over-year change of. This contributed to the annual value of $7.0 million for FY2024, which is 17.57% down from last year.
  • Ascentage Pharma Group International's Long-Term Deferred Tax amounted to $4.6 million in Q2 2025, which was down 33.87% from $7.0 million recorded in Q4 2024.
  • Ascentage Pharma Group International's Long-Term Deferred Tax's 5-year high stood at $8.4 million during Q4 2022, with a 5-year trough of $4.6 million in Q2 2025.
  • In the last 3 years, Ascentage Pharma Group International's Long-Term Deferred Tax had a median value of $7.0 million in 2024 and averaged $6.6 million.
  • Data for Ascentage Pharma Group International's Long-Term Deferred Tax shows a maximum YoY decreased of 16.02% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Ascentage Pharma Group International's Long-Term Deferred Tax stood at $8.4 million in 2022, then decreased by 0.86% to $8.3 million in 2023, then fell by 16.02% to $7.0 million in 2024, then reached $4.6 million in 2025.
  • Its Long-Term Deferred Tax was $4.6 million in Q2 2025, compared to $7.0 million in Q4 2024 and $8.3 million in Q4 2023.